Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Investments in San Diego County startups decreased by 35% in the second quarter compared to a year ago, marking it the third ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

U.S. stocks closed higher Friday, capping a choppy week of trading with the market's third winning week in the last four and ...

U.S. stocks are drifting near their record heights as Wall Street waits for an upcoming update on inflation.

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Legend Biotech announced its Q2 earnings, reporting $439m of revenues for its only commercial product, the cell therapy ...